Nephros Total Stockholder Equity from 2010 to 2024

NEPH Stock  USD 1.54  0.03  1.99%   
Nephros' Total Stockholder Equity is increasing with slightly volatile movements from year to year. Total Stockholder Equity is estimated to finish at about 8.8 M this year. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2003-12-31
Previous Quarter
7.9 M
Current Value
8.2 M
Quarterly Volatility
4.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nephros financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nephros' main balance sheet or income statement drivers, such as Depreciation And Amortization of 203.3 K, Interest Expense of 1.9 K or Total Revenue of 14.9 M, as well as many indicators such as Price To Sales Ratio of 2.4, Dividend Yield of 0.0144 or PTB Ratio of 3.48. Nephros financial statements analysis is a perfect complement when working with Nephros Valuation or Volatility modules.
  
Check out the analysis of Nephros Correlation against competitors.
For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

Latest Nephros' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Nephros over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Nephros' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nephros' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Nephros Total Stockholder Equity Regression Statistics

Arithmetic Mean3,149,114
Geometric Mean3,381,874
Coefficient Of Variation183.90
Mean Deviation4,449,614
Median2,664,000
Standard Deviation5,791,186
Sample Variance33.5T
Range20.5M
R-Value0.83
Mean Square Error11.2T
R-Squared0.69
Significance0.0001
Slope1,074,774
Total Sum of Squares469.5T

Nephros Total Stockholder Equity History

20248.8 M
20238.4 M
20225.6 M
202111.7 M
202012.5 M
20194.7 M
20183.8 M

About Nephros Financial Statements

Investors use fundamental indicators, such as Nephros' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Nephros' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Stockholder Equity8.4 M8.8 M

Currently Active Assets on Macroaxis

When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:
Check out the analysis of Nephros Correlation against competitors.
For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.09)
Revenue Per Share
1.313
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.08)
Return On Equity
(0.16)
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.